Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.

@article{Gameren1994EffectsOR,
  title={Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.},
  author={Mieke M van Gameren and P. H. Willemse and Nanno H. Mulder and Pieter C. Limburg and Harry J. M. Groen and Edo Vellenga and E G E Liesbeth de Vries},
  journal={Blood},
  year={1994},
  volume={84 5},
  pages={1434-41}
}
To define the toxicity profile of recombinant human interleukin-6 (rhIL-6) and to study its effect on hematopoiesis, biochemical parameters and other cytokines, rhIL-6 was administered in a phase I-II study to 20 patients with breast carcinoma or nonsmall cell lung cancer. RhIL-6 doses were 0.5, 1.0, 2.5, 5.0, 10, and 20 micrograms/kg/d, with at least three… CONTINUE READING